ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
0.00%
Gold vs US Dollar
2,325.355
1.37%
Brent Oil
83.30
0.21%
Bitcoin
63,628.23
-0.57%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lexaria Bioscience Corporation (LEXX)

  7. Lexaria Bioscience Corporation (LEXX) News

Lexaria Bioscience (LEXX)

Lexaria Bioscience Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LEXX
DateTimeSourceHeadlineSymbolCompany
06/03/202411:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LEXXLexaria Bioscience Corporation
01/03/202419:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202420:47Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202411:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LEXXLexaria Bioscience Corporation
14/02/202419:20Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
14/02/202417:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
30/01/202418:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
29/01/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LEXXLexaria Bioscience Corporation
24/01/202419:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
24/01/202418:33Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:LEXXLexaria Bioscience Corporation
18/01/202419:38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEXXLexaria Bioscience Corporation
12/01/202422:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LEXXLexaria Bioscience Corporation
11/01/202413:30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamNASDAQ:LEXXLexaria Bioscience Corporation
10/01/202413:45InvestorsHub NewsWireGLP-1: Beyond Diabetes, a Blockbuster Horizon BeckonsNASDAQ:LEXXLexaria Bioscience Corporation
09/01/202413:30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery PlatformNASDAQ:LEXXLexaria Bioscience Corporation
08/01/202413:45InvestorsHub NewsWireExciting New Cures Possible from GLP-1 Diabetes, Weight-Loss DrugsNASDAQ:LEXXLexaria Bioscience Corporation
04/01/202422:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
11/12/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LEXXLexaria Bioscience Corporation
08/12/202321:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LEXXLexaria Bioscience Corporation
30/11/202321:14Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:LEXXLexaria Bioscience Corporation
20/11/202322:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LEXXLexaria Bioscience Corporation
03/11/202317:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202317:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202312:45InvestorsHub NewsWireGet Ready for Next Generation of Diabetes, Weight-Management DrugsNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202312:30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug SpaceNASDAQ:LEXXLexaria Bioscience Corporation
31/10/202312:31GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 DrugsNASDAQ:LEXXLexaria Bioscience Corporation
30/10/202316:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LEXXLexaria Bioscience Corporation
30/10/202312:45InvestorsHub NewsWireCan Diabetes, Weight-Loss Drugs Get Even Better?NASDAQ:LEXXLexaria Bioscience Corporation
18/10/202317:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
 Showing the most relevant articles for your search:NASDAQ:LEXX

Your Recent History

LSE
POS
Plexus
LSE
RR.
Rolls-royce
LSE
SRSP
Sirius Petroleum
LSE
SBTX
Skinbiotherapeutics
LSE
AAU
Ariana Resources
LSE
HUM
Hummingbird Resources
LSE
BIRD
Blackbird
LSE
SCE
Surface Transforms
LSE
ENET
Ethernity Networks
LSE
AGL
Angle
LSE
SOLG
Solgold
LSE
LLOY
Lloyds Banking
LSE
GFM
Griffin Mining
LSE
INSG
Insig Ai
LSE
OBI
Ondine Biomedical
LSE
OXB
Oxford Biomedica
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved